AR089673A1 - Formulacion de premezcla de dexmedetomidina - Google Patents

Formulacion de premezcla de dexmedetomidina

Info

Publication number
AR089673A1
AR089673A1 ARP130100046A ARP130100046A AR089673A1 AR 089673 A1 AR089673 A1 AR 089673A1 AR P130100046 A ARP130100046 A AR P130100046A AR P130100046 A ARP130100046 A AR P130100046A AR 089673 A1 AR089673 A1 AR 089673A1
Authority
AR
Argentina
Prior art keywords
dexmedetomidine
liquid
composition
subject
concentration
Prior art date
Application number
ARP130100046A
Other languages
English (en)
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46613447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089673(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Inc filed Critical Hospira Inc
Publication of AR089673A1 publication Critical patent/AR089673A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composiciones farmacéuticas que comprenden dexmedetomidina o una sal farmacéuticamente aceptable de la misma en donde la composición se formula como un líquido para la administración parenteral a un sujeto, y en donde la composición se dispone dentro de un contenedor sellado como una premezcla. Las composiciones farmacéuticas se pueden utilizar, por ejemplo, en el cuidado perioperativo de un paciente o para la sedación. Reivindicación 1: Una composición farmacéutica líquida lista para el uso para la administración parenteral a un sujeto, caracterizada en que comprende dexmedetomidina o una sal farmacéuticamente aceptable de la misma en una concentración de aproximadamente 0.005 a aproximadamente 50 mg/mL, dispuesta dentro de un contenedor de vidrio sellado. Reivindicación 6: La composición farmacéutica líquida lista para el uso de la reivindicación 1, caracterizada en que adicionalmente comprende cloruro de sodio en una concentración de entre aproximadamente 0.01 y aproximadamente 2.0 por ciento en peso.
ARP130100046A 2012-01-04 2013-01-04 Formulacion de premezcla de dexmedetomidina AR089673A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/343,672 US8242158B1 (en) 2012-01-04 2012-01-04 Dexmedetomidine premix formulation

Publications (1)

Publication Number Publication Date
AR089673A1 true AR089673A1 (es) 2014-09-10

Family

ID=46613447

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130100046A AR089673A1 (es) 2012-01-04 2013-01-04 Formulacion de premezcla de dexmedetomidina
ARP190103245A AR117001A2 (es) 2012-01-04 2019-11-06 Formulación de premezcla de dexmedetomidina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190103245A AR117001A2 (es) 2012-01-04 2019-11-06 Formulación de premezcla de dexmedetomidina

Country Status (35)

Country Link
US (10) US8242158B1 (es)
EP (2) EP3345599A1 (es)
JP (4) JP5892177B2 (es)
KR (1) KR101632103B1 (es)
CN (2) CN103281902A (es)
AR (2) AR089673A1 (es)
AU (1) AU2013201069B1 (es)
BR (1) BR112013008005A8 (es)
CA (1) CA2806706C (es)
CL (1) CL2013000815A1 (es)
CO (1) CO6680698A2 (es)
CY (1) CY1120521T1 (es)
DK (1) DK2648520T3 (es)
EC (1) ECSP13012569A (es)
ES (1) ES2671749T3 (es)
GT (1) GT201300055A (es)
HK (1) HK1249429A1 (es)
HR (1) HRP20180838T1 (es)
HU (1) HUE038128T2 (es)
IL (1) IL224867B (es)
LT (1) LT2648520T (es)
MX (1) MX2013003629A (es)
MY (2) MY161022A (es)
PE (2) PE20131166A1 (es)
PL (1) PL2648520T3 (es)
PT (1) PT2648520T (es)
RS (1) RS57346B1 (es)
SA (2) SA113340176B1 (es)
SG (1) SG191706A1 (es)
SI (1) SI2648520T1 (es)
TR (1) TR201809123T4 (es)
TW (2) TWI593409B (es)
UY (1) UY34562A (es)
WO (1) WO2013103378A1 (es)
ZA (1) ZA201301649B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
KR101881791B1 (ko) * 2013-10-07 2018-07-25 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
WO2015094392A1 (en) * 2013-12-18 2015-06-25 Gnt, Llc Compositions and methods for treatment of glaucoma
FI127534B (en) * 2014-11-10 2018-08-31 Vetcare Oy Substituted benzoefuroquinolizine and ɑ2-adrenergic agonist comprising compositions
CN106038538A (zh) * 2015-04-17 2016-10-26 江苏恒瑞医药股份有限公司 一种右美托咪定的预混合制剂
CN105168122B (zh) * 2015-09-24 2018-11-27 辰欣药业股份有限公司 一种盐酸右美托咪定注射液及其制备工艺
US10632043B2 (en) * 2015-11-11 2020-04-28 Aurobindo Pharma Ltd Premix formulation for parenteral use and packaging thereof
US20170128421A1 (en) * 2015-11-11 2017-05-11 Siva Prasad Reddy Sura Premix formulation for parenteral use and packaging thereof
US9717796B1 (en) * 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
CN107412152B (zh) * 2016-05-24 2020-12-04 海南合瑞制药股份有限公司 一种盐酸右美托咪定注射液组合物
CN110114069B (zh) * 2016-12-26 2022-03-04 久光制药株式会社 微针装置
JP6868698B2 (ja) 2016-12-31 2021-05-12 バイオエクセル セラピューティクス，インコーポレイテッド 激越の治療のための舌下デクスメデトミジンの使用
CN107028880A (zh) * 2017-06-09 2017-08-11 安徽赛诺制药有限公司 一种盐酸右美托咪定注射液的生产工艺
US20190262314A1 (en) * 2018-02-26 2019-08-29 Slayback Pharma Llc Ready-to-use dexmedetomidine compositions
CN108956809B (zh) * 2018-06-04 2021-03-23 四川科伦药物研究院有限公司 一种检测1-(1-氯乙基)-2,3-二甲苯有关物质的方法
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
WO2020006119A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Methods for treating agitation using dexmedetomidine hydrochloride
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN109081811A (zh) * 2018-09-19 2018-12-25 南京正大天晴制药有限公司 盐酸右美托咪定的有关物质及其制备方法
JP2019048091A (ja) * 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
CN116615243A (zh) * 2020-10-08 2023-08-18 比奥克斯塞尔医疗股份有限公司 使用右美托咪啶盐酸盐治疗躁郁症和精神病
EP4085891A1 (en) 2021-05-05 2022-11-09 B. Braun Melsungen AG Dexmedetomidine-solution in a low-density polyethylene container
CN113041242A (zh) * 2021-05-18 2021-06-29 上海交通大学医学院附属仁济医院 右美托咪定在促进肝脏再生中的应用
CN113116815A (zh) * 2021-06-07 2021-07-16 辰欣药业股份有限公司 一种盐酸右美托咪定注射液的制备方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
JPS6058890A (ja) 1983-09-13 1985-04-05 Mizusawa Ind Chem Ltd 感熱記録紙用填剤
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5344840A (en) 1988-02-29 1994-09-06 Orion-Yhtyma Oy 4-substituted imidazole derivatives useful in perioperative care
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
BR9508554A (pt) * 1994-08-08 1997-11-25 Debiopharm Sa Preparação farmaceuticamente estável de oxaliplatina
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
EP1121933A1 (en) 2000-02-02 2001-08-08 Pfizer Products Inc. Premixed alatrofloxacin injectable compositions
US6310094B1 (en) 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
HUP0304086A3 (en) 2001-03-29 2005-02-28 Baxter Internat Inc Deerfield Premixed amiodarone solution for parenteral use and method for making the same
US6806291B1 (en) * 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them
BRPI0604377A (pt) 2006-10-27 2008-06-24 Cristalia Prod Quimicos Farm microemulsão óleo/água de propofol estável e pronta-para-uso
US20080308444A1 (en) * 2007-06-13 2008-12-18 Baxter International Inc. Packaging system and method of alerting a practitioner
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8100890B2 (en) * 2008-10-15 2012-01-24 Bioquiddity, Inc. Special purpose fluid dispenser with pre-filled reservoir
EP2363147B1 (en) 2008-10-30 2016-02-24 National University Corporation Okayama University Composition for local anesthesia
CN106511273A (zh) 2009-05-15 2017-03-22 瑞克欧制药有限公司 舌下右美托咪定组合物及其使用方法
US8410140B2 (en) * 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
EP2459170A2 (en) 2009-07-31 2012-06-06 Astron Research Limited A stable composition of ready-to-use gemcitabine injection
US20110152271A1 (en) 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation

Also Published As

Publication number Publication date
CO6680698A2 (es) 2013-05-31
HK1249429A1 (zh) 2018-11-02
UY34562A (es) 2014-07-31
JP5990832B2 (ja) 2016-09-14
HUE038128T2 (hu) 2018-09-28
MY161022A (en) 2017-03-31
TW201630603A (zh) 2016-09-01
HRP20180838T1 (hr) 2018-06-29
MY188598A (en) 2021-12-22
ECSP13012569A (es) 2015-04-30
CN103281902A (zh) 2013-09-04
BR112013008005A2 (pt) 2016-06-14
AU2013201069B1 (en) 2013-08-15
US8338470B1 (en) 2012-12-25
EP2648520A1 (en) 2013-10-16
US20170165235A1 (en) 2017-06-15
MX2013003629A (es) 2013-11-05
RS57346B1 (sr) 2018-08-31
PE20160681A1 (es) 2016-07-28
LT2648520T (lt) 2018-07-10
GT201300055A (es) 2014-08-26
CY1120521T1 (el) 2019-07-10
PE20131166A1 (es) 2013-10-05
CA2806706C (en) 2015-07-14
SG191706A1 (en) 2013-08-30
US8436033B1 (en) 2013-05-07
WO2013103378A1 (en) 2013-07-11
AR117001A2 (es) 2021-06-30
JP2014508746A (ja) 2014-04-10
US20180289673A1 (en) 2018-10-11
US20130237576A1 (en) 2013-09-12
EP3345599A1 (en) 2018-07-11
SA115360458B1 (ar) 2016-01-27
KR20140096238A (ko) 2014-08-05
US8242158B1 (en) 2012-08-14
IL224867A0 (en) 2013-06-27
US20140155446A1 (en) 2014-06-05
SI2648520T1 (en) 2018-08-31
PT2648520T (pt) 2018-06-06
TWI574688B (zh) 2017-03-21
JP2014088433A (ja) 2014-05-15
KR101632103B1 (ko) 2016-06-20
TW201332546A (zh) 2013-08-16
SA113340176B1 (ar) 2015-07-26
US8648106B2 (en) 2014-02-11
US20160175285A1 (en) 2016-06-23
TR201809123T4 (tr) 2018-07-23
US20180289674A1 (en) 2018-10-11
IL224867B (en) 2018-01-31
BR112013008005A8 (pt) 2018-01-09
CA2806706A1 (en) 2013-07-04
ES2671749T3 (es) 2018-06-08
JP2015110639A (ja) 2015-06-18
CL2013000815A1 (es) 2013-09-06
US8455527B1 (en) 2013-06-04
JP5927680B2 (ja) 2016-06-01
JP5892177B2 (ja) 2016-03-23
DK2648520T3 (en) 2018-06-18
ZA201301649B (en) 2014-08-27
US10016396B2 (en) 2018-07-10
JP2014058577A (ja) 2014-04-03
TWI593409B (zh) 2017-08-01
CN107802624A (zh) 2018-03-16
US9320712B2 (en) 2016-04-26
NZ607555A (en) 2015-08-28
EP2648520B1 (en) 2018-04-11
PL2648520T3 (pl) 2018-08-31
US9616049B2 (en) 2017-04-11
EP2648520A4 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
AR089673A1 (es) Formulacion de premezcla de dexmedetomidina
TR201904614T4 (tr) Novel pyrazole derivative.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
ECSP088903A (es) Composiciones farmacéuticas de anticuerpo antagonista anti-cd40
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
UY32602A (es) Formulación para la administración oral de un promotor de apoptosis
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
CR20150367A (es) Compuestos químicos
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
BR112015014433A2 (pt) compostos tricíclicos
EA201501163A1 (ru) Модуляторы рецептора cxcr7
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120
EA201490573A1 (ru) Соединение бензотиазолона
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
AR090244A1 (es) Formulacion de anticuerpo anti-selectina p
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола

Legal Events

Date Code Title Description
FC Refusal